Overview

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Status:
Recruiting
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Beacon Therapeutics